143 related articles for article (PubMed ID: 35456436)
1. Technological Advances:
Akabari R; Qin D; Hussaini M
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456436
[TBL] [Abstract][Full Text] [Related]
2. Accurate Detection and Quantification of FLT3 Internal Tandem Duplications in Clinical Hybrid Capture Next-Generation Sequencing Data.
Tung JK; Suarez CJ; Chiang T; Zehnder JL; Stehr H
J Mol Diagn; 2021 Oct; 23(10):1404-1413. PubMed ID: 34363960
[TBL] [Abstract][Full Text] [Related]
3. Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis.
He R; Devine DJ; Tu ZJ; Mai M; Chen D; Nguyen PL; Oliveira JL; Hoyer JD; Reichard KK; Ollila PL; Al-Kali A; Tefferi A; Begna KH; Patnaik MM; Alkhateeb H; Viswanatha DS
Mod Pathol; 2020 Mar; 33(3):334-343. PubMed ID: 31471587
[TBL] [Abstract][Full Text] [Related]
4. Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data.
Spencer DH; Abel HJ; Lockwood CM; Payton JE; Szankasi P; Kelley TW; Kulkarni S; Pfeifer JD; Duncavage EJ
J Mol Diagn; 2013 Jan; 15(1):81-93. PubMed ID: 23159595
[TBL] [Abstract][Full Text] [Related]
5. Detection the Frequency and Characteristics of FLT3 Internal Tandem Duplication Mutations by Capillary Electrophoresis Assay and Next-Generation Sequencing in.
Ma L; Cao Y; Jiang Y; Cong X; Lu S; Shen J; Liu Q; Han C; Zhan Y; Cao Y
Clin Lab; 2016 Oct; 62(10):2065-2072. PubMed ID: 28164543
[TBL] [Abstract][Full Text] [Related]
6. A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms.
Behdad A; Weigelin HC; Elenitoba-Johnson KS; Betz BL
J Mol Diagn; 2015 Jan; 17(1):76-84. PubMed ID: 25468431
[TBL] [Abstract][Full Text] [Related]
7. Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms.
Tsai HK; Brackett DG; Szeto D; Frazier R; MacLeay A; Davineni P; Manning DK; Garcia E; Lindeman NI; Le LP; Lennerz JK; Gibson CJ; Lindsley RC; Kim AS; Nardi V
J Mol Diagn; 2020 Sep; 22(9):1162-1178. PubMed ID: 32603763
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
Port M; Böttcher M; Thol F; Ganser A; Schlenk R; Wasem J; Neumann A; Pouryamout L
Ann Hematol; 2014 Aug; 93(8):1279-86. PubMed ID: 24801015
[TBL] [Abstract][Full Text] [Related]
10. A DNA pool of FLT3-ITD positive DNA samples can be used efficiently for analytical evaluation of NGS-based FLT3-ITD quantitation - Testing several different ITD sequences and rates, simultaneously.
Mezei ZA; Tornai D; Földesi R; Madar L; Sümegi A; Papp M; Antal-Szalmás P
J Biotechnol; 2019 Sep; 303():25-29. PubMed ID: 31302157
[TBL] [Abstract][Full Text] [Related]
11. ITDetect: a method to detect internal tandem duplication of FMS-like tyrosine kinase (FLT3) from next-generation sequencing data with high sensitivity and clinical application.
Lee S; Sun CH; Jang H; Kim D; Yoon SS; Koh Y; Na SC; Cho SI; Kim MJ; Seong MW; Byun JM; Yun H
BMC Bioinformatics; 2023 Feb; 24(1):62. PubMed ID: 36823555
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of next-generation sequencing and fragment analysis for the detection and allelic ratio determination of FLT3 internal tandem duplication.
Kim JJ; Lee KS; Lee TG; Lee S; Shin S; Lee ST
Diagn Pathol; 2022 Jan; 17(1):14. PubMed ID: 35081962
[TBL] [Abstract][Full Text] [Related]
13. ITD assembler: an algorithm for internal tandem duplication discovery from short-read sequencing data.
Rustagi N; Hampton OA; Li J; Xi L; Gibbs RA; Plon SE; Kimmel M; Wheeler DA
BMC Bioinformatics; 2016 Apr; 17():188. PubMed ID: 27121965
[TBL] [Abstract][Full Text] [Related]
14. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
[TBL] [Abstract][Full Text] [Related]
15. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.
Au CH; Wa A; Ho DN; Chan TL; Ma ES
Diagn Pathol; 2016 Jan; 11():11. PubMed ID: 26796102
[TBL] [Abstract][Full Text] [Related]
17. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
Park SH; Chi HS; Cho YU; Jang S; Park CJ
Leuk Res; 2013 Nov; 37(11):1488-94. PubMed ID: 24054719
[TBL] [Abstract][Full Text] [Related]
18. Nanopore Targeted Sequencing for Rapid Gene Mutations Detection in Acute Myeloid Leukemia.
Cumbo C; Minervini CF; Orsini P; Anelli L; Zagaria A; Minervini A; Coccaro N; Impera L; Tota G; Parciante E; Conserva MR; Spinelli O; Rambaldi A; Specchia G; Albano F
Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31835432
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
20. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
Marhäll A; Heidel F; Fischer T; Rönnstrand L
Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
